APP and Alzheimer disease: Animal studies have illustrated that a lack of APOA-I exacerbates—while overexpression of human APOA-I alleviates—CAA in the APP/PS1 mouse model of AD, without affecting parenchymal Aβ deposition [83,84], consistent with a prior study in a different line of APOA-I-deficient AD mice (PD-APP) [85].